Yoshihiko Kanno

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8368992/publications.pdf

Version: 2024-02-01

144 papers	4,746 citations	147801 31 h-index	106344 65 g-index
152 all docs	152 docs citations	152 times ranked	4817 citing authors

#	Article	IF	Citations
1	The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertension Research, 2019, 42, 1235-1481.	2.7	1,047
2	Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet, The, 2021, 397, 1625-1636.	13.7	414
3	Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. American Journal of Kidney Diseases, 2004, 43, 1056-1064.	1.9	184
4	Effect of Angiotensin Receptor Blockers on Cardiovascular Events in Patients Undergoing Hemodialysis: An Open-Label Randomized Controlled Trial. American Journal of Kidney Diseases, 2008, 52, 501-506.	1.9	173
5	A case-control study of calciphylaxis in Japanese end-stage renal disease patients. Nephrology Dialysis Transplantation, 2012, 27, 1580-1584.	0.7	173
6	Connective Tissue Growth Factor Expressed in Tubular Epithelium Plays a Pivotal Role in Renal Fibrogenesis. Journal of the American Society of Nephrology: JASN, 2005, 16, 133-143.	6.1	170
7	A new Classification of Diabetic Nephropathy 2014: a report from Joint Committee on Diabetic Nephropathy. Journal of Diabetes Investigation, 2015, 6, 242-246.	2.4	157
8	Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. Lancet, The, 2021, 398, 1053-1064.	13.7	133
9	Hepatocyte growth factor counteracts transforming growth factorâ€β1, through attenuation of connective tissue growth factor induction, and prevents renal fibrogenesis in 5/6 nephrectomized mice. FASEB Journal, 2003, 17, 268-270.	0.5	128
10	Newly Developed Immobilized Polymyxin B Fibers Improve the Survival of Patients with Sepsis. Blood Purification, 2001, 19, 361-369.	1.8	106
11	Low Doses of Losartan and Trandolapril Improve Arterial Stiffness in Hemodialysis Patients. American Journal of Kidney Diseases, 2005, 45, 866-874.	1.9	81
12	Effects of Candesartan on Cardiovascular Outcomes in Japanese Hypertensive Patients. Hypertension Research, 2005, 28, 307-314.	2.7	77
13	Uric Acid Level Has a U-Shaped Association with Loss of Kidney Function in Healthy People: A Prospective Cohort Study. PLoS ONE, 2015, 10, e0118031.	2.5	73
14	Qualification of Arterial Stiffness as a Risk Factor to the Progression of Chronic Kidney Diseases. American Journal of Nephrology, 2005, 25, 417-424.	3.1	65
15	<scp>COVID</scp>â€19 of dialysis patients in Japan: Current status and guidance on preventive measures. Therapeutic Apheresis and Dialysis, 2020, 24, 361-365.	0.9	53
16	Short- and long-term prognosis of blood pressure and kidney disease in women with a past history of preeclampsia. Clinical and Experimental Nephrology, 2008, 12, 102-109.	1.6	52
17	A new nutritional risk index for predicting mortality in hemodialysis patients: Nationwide cohort study. PLoS ONE, 2019, 14, e0214524.	2.5	51
18	Add-On Angiotensin Receptor Blocker in Patients Who Have Proteinuric Chronic Kidney Diseases and Are Treated with Angiotensin-Converting Enzyme Inhibitors. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 730-737.	4.5	50

#	Article	IF	Citations
19	Role of chloride channels in afferent arteriolar constriction. Kidney International, 1996, 50, 864-872.	5.2	49
20	Bradykinin Decreases Plasminogen Activator Inhibitor-1 Expression and Facilitates Matrix Degradation in the Renal Tubulointerstitium under Angiotensin-Converting Enzyme Blockade. Journal of the American Society of Nephrology: JASN, 2004, 15, 2404-2413.	6.1	46
21	Cilnidipine Is As Effective As Benazepril for Control of Blood Pressure and Proteinuria in Hypertensive Patients with Benign Nephrosclerosis.. Hypertension Research, 2001, 24, 377-383.	2.7	44
22	Connective tissue growth factor mediates the profibrotic effects of transforming growth factor-Î² produced by tubular epithelial cells in response to high glucose. Clinical and Experimental Nephrology, 2005, 9, 114-121.	1.6	44
23	Dexamethasone Induces Connective Tissue Growth Factor Expression in Renal Tubular Epithelial Cells in a Mouse Strain-Specific Manner. American Journal of Pathology, 2006, 168, 737-747.	3.8	42
24	Angiotensin Receptor Antagonist Regresses Left Ventricular Hypertrophy Associated with Diabetic Nephropathy in Dialysis Patients. Journal of Cardiovascular Pharmacology, 2004, 43, 380-386.	1.9	41
25	A Possible Anti-Inflammatory Role of Angiotensin II Type 2 Receptor in Immune-Mediated Glomerulonephritis during Type 1 Receptor Blockade. American Journal of Pathology, 2006, 169, 1577-1589.	3.8	41
26	Transient receptor potential channels in rat renal microcirculation: Actions of angiotensin II. Kidney International, 2002, 62, 558-565.	5.2	40
27	A selective angiotensin receptor antagonist, Valsartan, produced regression of left ventricular hypertrophy associated with a reduction of arterial stiffness. Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis, 2003, 19, 59-66.	0.1	39
28	Selective depletion of fibroblasts preserves morphology and the functional integrity of peritoneum in transgenic mice with peritoneal fibrosing syndrome. Kidney International, 2003, 64, 1722-1732.	5.2	38
29	Key role of insulin resistance in vascular injury among hemodialysis patients. Metabolism: Clinical and Experimental, 2007, 56, 153-159.	3.4	38
30	Vitamin B6 supplementation can improve peripheral polyneuropathy in patients with chronic renal failure on highâ€flux haemodialysis and human recombinant erythropoietin. Nephrology Dialysis Transplantation, 2000, 15, 1410-1413.	0.7	34
31	Survival and predictive factors in dialysis patients with COVID-19 in Japan: a nationwide cohort study. Renal Replacement Therapy, 2021, 7, 59.	0.7	34
32	Systemic Capillary Leak Syndrome.. Internal Medicine, 2002, 41, 953-956.	0.7	32
33	Transgene-derived hepatocyte growth factor attenuates reactive renal fibrosis in aristolochic acid nephrotoxicity. Nephrology Dialysis Transplantation, 2003, 18, 2515-2523.	0.7	31
34	Guideline on the use of iodinated contrast media in patients with kidney disease 2018. Clinical and Experimental Nephrology, 2020, 24, 1-44.	1.6	31
35	Interleukin-4 Expression in Mesangial Proliferative Glomerulonephritis. American Journal of Kidney Diseases, 1994, 23, 242-246.	1.9	30
36	Interstitial Fibroblast-Like Cells Express Renin-Angiotensin System Components in a Fibrosing Murine Kidney. American Journal of Pathology, 2002, 160, 765-772.	3.8	29

#	Article	IF	Citations
37	Absence of Increased Î±1-Microglobulin in IgA Nephropathy Proteinuria. Molecular and Cellular Proteomics, 2007, 6, 738-744.	3.8	29
38	Effects of Eplerenone on Heart and Kidney in Two-Kidney, One-Clip Rats. American Journal of Nephrology, 2004, 24, 54-60.	3.1	28
39	An Angiotensin Receptor Blocker Reduces the Risk of Congestive Heart Failure in Elderly Hypertensive Patients with Renal Insufficiency. Hypertension Research, 2005, 28, 415-423.	2.7	27
40	A Fiveyear Comparison of the Renal Protective Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients with NonDiabeticNephropathy. Internal Medicine, 2006, 45, 193-198.	0.7	27
41	Poly(ADP-Ribose) Polymerase-1 Enhances Transcription of the Profibrotic CCN2 Gene. Journal of the American Society of Nephrology: JASN, 2008, 19, 933-942.	6.1	27
42	Water-Permeable Dialysis Membranes for Multi-Layered Microdialysis System. Frontiers in Bioengineering and Biotechnology, 2015, 3, 70.	4.1	27
43	Effects of Endocrine Disrupting Substance on Estrogen Receptor Gene Transcription in Dialysis Patients. Therapeutic Apheresis and Dialysis, 2007, 11, 262-265.	0.9	26
44	Renal fibroblast-like cells in Goodpasture syndrome rats. Kidney International, 2001, 60, 597-606.	5.2	25
45	Tubular expression of connective tissue growth factor correlates with interstitial fibrosis in type 2 diabetic nephropathy. Nephrology Dialysis Transplantation, 2006, 21, 548-549.	0.7	25
46	Antithrombogenicity of Fluorinated Diamond-Like Carbon Films Coated Nano Porous Polyethersulfone (PES) Membrane. Materials, 2013, 6, 4309-4323.	2.9	23
47	Renal Responses to Angiotensin Receptor Antagonist and Angiotensin-Converting Enzyme Inhibitor in Partially Nephrectomized Spontaneously Hypertensive Rats. Journal of Cardiovascular Pharmacology, 1995, 26, 564-569.	1.9	22
48	Angiotensin II type 1 receptor blockade attenuates renal fibrogenesis in an immune-mediated nephritic kidney through counter-activation of angiotensin II type 2 receptor. Biochemical and Biophysical Research Communications, 2004, 314, 403-408.	2.1	20
49	rAAV6-mediated miR-29b delivery suppresses renal fibrosis. Clinical and Experimental Nephrology, 2019, 23, 1345-1356.	1.6	19
50	Central blood pressure and chronic kidney disease. World Journal of Nephrology, 2016, 5, 90.	2.0	19
51	TGF-Î²1 and HGF coordinately facilitate collagen turnover in subepithelial mesenchyme. Biochemical and Biophysical Research Communications, 2002, 297, 255-260.	2.1	18
52	Estrogen and Angiotensin II Interactions Determine Cardio-Renal Damage in Dahl Salt-Sensitive Rats with Heart Failure. American Journal of Nephrology, 2008, 28, 413-423.	3.1	18
53	Comparison of the Effects of an ACE Inhibitor and .ALPHA..BETA. Blocker on the Progression of Renal Failure with Left Ventricular Hypertrophy: Preliminary Report.. Hypertension Research, 2001, 24, 153-158.	2.7	17
54	Direct Contact between Human Peripheral Blood Mononuclear Cells and Renal Fibroblasts Facilitates the Expression of Monocyte Chemoattractant Protein-1. American Journal of Nephrology, 2003, 23, 208-213.	3.1	17

#	Article	IF	Citations
55	Impact of Selectin Gene Polymorphisms on Rapid Progression to End-Stage Renal Disease in Patients with IgA Nephropathy. Internal Medicine, 2006, 45, 947-951.	0.7	17
56	Identifying progressive CKD from healthy population using Bayesian network and artificial intelligence: A worksite-based cohort study. Scientific Reports, 2019, 9, 5082.	3.3	17
57	Effects of Novel, Nonpeptide Vasopressin Antagonists on Progressive Nephrosclerosis in Rats. Journal of Cardiovascular Pharmacology, 1995, 25, 847-852.	1.9	16
58	Polyethersulfone Membrane Coated With Nanoporous Parylene for Ultrafiltration. Journal of Microelectromechanical Systems, 2012, 21, 1288-1290.	2.5	16
59	Long-Term Safety and Effectiveness of the Xanthine Oxidoreductase Inhibitor, Topiroxostat in Japanese Hyperuricemic Patients with or Without Gout: A 54-week Open-label, Multicenter, Post-marketing Observational Study. Clinical Drug Investigation, 2020, 40, 847-859.	2.2	16
60	Fructosamine Assay Using Albumin Extracted from Serum.. Biological and Pharmaceutical Bulletin, 2002, 25, 1121-1124.	1.4	15
61	Erythropoietin resistance in patients on continuous ambulatory peritoneal dialysis. Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis, 2004, 20, 111-6.	0.1	15
62	Interleukin (IL)-1 and IL-4 synergistically stimulate NF-IL6 activity and IL-6 production in human mesangial cells. Kidney International, 1998, 54, 71-79.	5.2	14
63	Decline of Renal Function Is Associated with Proteinuria and Systolic Blood Pressure in the Morning in Diabetic Nephropathy. Clinical and Experimental Hypertension, 2005, 27, 129-138.	1.3	14
64	Comparison and survival of patients receiving hemodialysis and peritoneal dialysis in a single center. Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis, 2007, 23, 144-9.	0.1	14
65	Estimation of daily protein intake based on spot urine urea nitrogen concentration in chronic kidney disease patients. Clinical and Experimental Nephrology, 2016, 20, 258-264.	1.6	13
66	Permeability and blood compatibility of nanoporous parylene filmâ€coated polyethersulfone membrane under longâ€term blood diffusion. Journal of Applied Polymer Science, 2014, 131, .	2.6	12
67	Safety of warfarin therapy in chronic hemodialysis patients: a prospective cohort study. Clinical and Experimental Nephrology, 2016, 20, 787-794.	1.6	12
68	Effectiveness of <scp>SARSâ€CoV</scp>â€2 vaccines on hemodialysis patients in Japan: A nationwide cohort study. Therapeutic Apheresis and Dialysis, 2023, 27, 19-23.	0.9	12
69	Selection of the Dose of Angiotensin Converting Enzyme Inhibitor for Patients with Diabetic Nephropathy Depends on the Presence or Absence of Left Ventricular Hypertorphy.. Hypertension Research, 2002, 25, 865-873.	2.7	11
70	Methods and Nutritional Interventions to Improve the Nutritional Status of Dialysis Patients in JAPANâ€”A Narrative Review. Nutrients, 2021, 13, 1390.	4.1	11
71	Elevation of plasma D-dimer is closely associated with venous thrombosis produced by double-lumen catheter in pre-dialysis patients. Nephrology Dialysis Transplantation, 2007, 22, 1224-1227.	0.7	10
72	A new classification of Diabetic Nephropathy 2014: a report from Joint Committee on Diabetic Nephropathy. Diabetology International, 2014, 5, 207-211.	1.4	10

#	Article	IF	Citations
73	The effect of small dose of topiroxostat on serum uric acid in patients receiving hemodialysis. Hemodialysis International, 2018, 22, 388-393.	0.9	10
74	Cross-sectional small intestinal surveillance of maintenance hemodialysis patients using video capsule endoscopy: SCHEMA study. Endoscopy International Open, 2016, 04, E589-E596.	1.8	9
75	Guideline on the use of iodinated contrast media in patients with kidney disease 2018. Japanese Journal of Radiology, 2020, 38, 3-46.	2.4	9
76	Evaluation of the efficacy of granulocyte and monocyte adsorption apheresis on skin manifestation and joint symptoms of patients with pustulotic arthroâ€osteitis. Journal of Dermatology, 2019, 46, 144-148.	1.2	8
77	Gastric angiodysplasia in patients undergoing maintenance dialysis. Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis, 2003, 19, 136-42.	0.1	8
78	Peritoneal dialysis versus hemodialysis: a five-year comparison of survival and effects on the cardiovascular system, erythropoiesis, and calcium metabolism. Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis, 2003, 19, 148-54.	0.1	8
79	Comparison of changes in pulse wave velocity in patients on continuous ambulatory peritoneal dialysis and hemodialysis one year after introduction of dialysis therapy. Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis, 2005, 21, 139-45.	0.1	8
80	Role of T lymphocytes in renal disease in HIV-transgenic mice. American Journal of Kidney Diseases, 2000, 35, 408-417.	1.9	7
81	A comparison of corticosteroid and warfarin therapy in IgA nephropathy with crescent formation: preliminary trial. Clinical and Experimental Nephrology, 2003, 7, 48-51.	1.6	7
82	Angiotensin II Type 1 and Type 2 Receptors Reciprocally Modulate Pro-inflammatory/ Pro-Fibrotic Reactions in Activated Splenic Lymphocytes. American Journal of Nephrology, 2004, 24, 322-329.	3.1	7
83	Cellular insulin resistance in Epstein-Barr virus-transformed lymphoblasts from young insulin-resistant Japanese men. Metabolism: Clinical and Experimental, 2005, 54, 370-375.	3.4	7
84	L-Carnitine improves gastrointestinal disorders and altered the intestinal microbiota in hemodialysis patients. Bioscience of Microbiota, Food and Health, 2017, 36, 11-16.	1.8	7
85	Acquired Idiopathic Pure Red Cell Aplasia in a Hemodialyzed Patient with Inactive Systemic Lupus Erythematosus.. Internal Medicine, 1994, 33, 492-495.	0.7	6
86	Electropolishing of Microchannels and its Application to Dialysis System. Procedia CIRP, 2013, 5, 164-168.	1.9	6
87	Dietary intake in Japanese patients with kidney transplantation. Clinical and Experimental Nephrology, 2016, 20, 972-981.	1.6	6
88	Glomerulonephritis Caused by Bartonella spp. Infective Endocarditis: The Difficulty and Importance of Differentiation from Anti-neutrophil Cytoplasmic Antibody-related Rapidly Progressive Glomerulonephritis. Internal Medicine, 2021, 60, 1899-1906.	0.7	6
89	Judicious Usage of Estrogen/Progesterone for Angiodysplasia. Artificial Organs, 2005, 29, 88-89.	1.9	5
90	Nutritional Assessment by a New Method for Patients with Renal Disease. , 2007, 155, 29-39.		5

#	Article	IF	Citations
91	Malnutrition as cause of hypomagnesemia. Kidney International, 2014, 86, 856.	5.2	5
92	Comparison of accuracy between pre-hemodialysis and post-hemodialysis levels of nutritional factors for prediction of mortality in hemodialysis patients. Clinical Nutrition, 2019, 38, 383-388.	5.0	5
93	The Effects of Antihypertensive Agents on the Survival Rate of Polycystic Kideney Disease in Han: SPRD Rats.. Hypertension Research, 2002, 25, 939-943.	2.7	5
94	Improved Outcome Prediction for Patients with Multiple Organ Failure Undergoing Continuous Hemodiafiltration. Therapeutic Apheresis and Dialysis, 2001, 5, 31-35.	0.9	4
95	Ticlopidine induces lupus in a haemodialysis patient. Nephrology Dialysis Transplantation, 2004, 19, 2685-2686.	0.7	4
96	Classification of Diabetic Nephropathy 2014. Nihon Toseki Igakkai Zasshi, 2014, 47, 415-419.	0.1	4
97	Association between visit-to-visit clinic blood pressure variability and home blood pressure variability in patients with chronic kidney disease. Renal Failure, 2015, 37, 446-451.	2.1	4
98	Evaluation of biofouling in stainless microfluidic channels for implantable multilayered dialysis device. Japanese Journal of Applied Physics, 2017, 56, 06GN10.	1.5	4
99	Dehydroxymethylepoxyquinomicin, a novel nuclear factor-Î¹B inhibitor, prevents the development of cyclosporine A nephrotoxicity in a rat model. BMC Pharmacology & Toxicology, 2020, 21, 60.	2.4	4
100	Structural changes in renal arterioles are closely associated with central hemodynamic parameters in patients with renal disease. Hypertension Research, 2021, 44, 1113-1121.	2.7	4
101	Evidence for Abnormalities in Parasympathetic Nerve-Mediated Reflexes in Borderline Hypertension.. Hypertension Research, 1993, 16, 185-190.	2.7	4
102	Renal Protective Effects of Amlodipine on Partially Nephrectomized Spontaneously Hypertensive Rats Fed a High-Salt Diet. Journal of Cardiovascular Pharmacology, 1994, 23, 480-484.	1.9	4
103	Relationship between dietary protein intake and the changes in creatinine clearance and glomerular cross-sectional area in patients with IgA nephropathy. Clinical and Experimental Nephrology, 2015, 19, 661-668.	1.6	3
104	An unusual form of crystal-forming chronic interstitial nephritis following long-term exposure to tosufloxacin tosilate. American Journal of Kidney Diseases, 2004, 44, 902-7.	1.9	3
105	Intensive Blood Pressure Reduction Is Beneficial in Patients with Impaired Cardiac Function Coexisting with Chronic Renal Insufficiency. Hypertension Research, 2002, 25, 41-48.	2.7	2
106	Selection of hemoperfusion therapy for patients with septic shock on the basis of the primary disease. Journal of Artificial Organs, 2003, 6, 205-210.	0.9	2
107	Congenic Substitution Mapping for Intracellular Ca2+ in Spontaneously Hypertensive Rats. American Journal of Hypertension, 2007, 20, 172-176.	2.0	2
108	Viruses may trigger allopurinol hypersensitivity syndrome. CKJ: Clinical Kidney Journal, 2008, 1, 273-274.	2.9	2

#	Article	IF	Citations
109	Evaluating central blood pressure in dialysis patients. Kidney International, 2015, 88, 193.	5.2	2
110	Blood pressure management in patients receiving renal replacement therapy. Hypertension Research, 2021, 44, 7-12.	2.7	2
111	The efficacy of pre-washed rice (Musenmai) on diet therapy for hemodialysis patients. Nihon Toseki Igakkai Zasshi, 2006, 39, 1187-1190.	0.1	2
112	Clinical feasibility of transfer to combined therapy with peritoneal dialysis and hemodialysis for patients on peritoneal dialysis: A prospective multicenter study in Japan. Therapeutic Apheresis and Dialysis, 2022, 26, 1226-1234.	0.9	2
113	Once-weekly hemodialysis helps continuous ambulatory peritoneal dialysis patients who have insufficient solute removal. Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis, 2003, 19, 143-7.	0.1	2
114	Residual renal function plays an important role in regulating parathyroid hormone in patients on continuous ambulatory peritoneal dialysis. Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis, 2007, 23, 150-4.	0.1	2
115	Close association of vascular and valvular calcification and prognosis of patients on continuous ambulatory peritoneal dialysis. Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis, 2008, 24, 60-4.	0.1	2
116	INFLUENCE OF THE TIMING OF INITIATING ANTIHYPERTENSIVE THERAPY IN HYPERTENSIVE RATS WITH RENAL FAILURE. Clinical and Experimental Hypertension, 2000, 22, 521-529.	1.3	1
117	Clinical Strategy for the Treatment of Hypertension in Non-Diabetic and Diabetic Nephropathy in Japan. , 2004, 143, 145-158.		1
118	Diet Therapy in Patients Receiving Peritoneal Dialysis. , 2007, 155, 72-81.		1
119	In vitro and in vivo tests of nanoporous membrane coated with biocompatible fluorine-doped diamond-like carbon for hemofiltration treatment. , 2018, , .		1
120	Hypertension as Three Systematic Dysregulations of Na+ Homeostasis in Terrestrial Mammal, and Salt in Gut Might Cause Brain Inflammation. , 0, , .		1
121	Pump-Free Microfluidic Hemofiltration Device. Micromachines, 2021, 12, 992.	2.9	1
122	The effect of blood flow on heart stroke volume during a hemodialysis session. Nihon Toseki Igakkai Zasshi, 2015, 48, 239-242.	0.1	1
123	Longitudinal changes of peritoneal function calculated by personal dialysis capacity in a patient after long-term continuous ambulatory peritoneal dialysis. Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis, 2003, 19, 97-102.	0.1	1
124	Anaphylactoid reaction to immunoadsorptive membrane in a patient with myasthenia gravis. CEN Case Reports, 2012, 1, 1-3.	0.9	0
125	Factors affecting decline of residual renal function in maintenance hemodialysis patients. Nihon Toseki Igakkai Zasshi, 2014, 47, 629-636.	0.1	0
126	Calf circumference measurement for nutritional assessment in maintenance hemodialysis patients. Nihon Toseki Igakkai Zasshi, 2014, 47, 679-684.	0.1	0

#	Article	IF	Citations
127	Grounds for withdrawing dialysis treatment under criminal law. Nihon Toseki Igakkai Zasshi, 2016, 49, 561-569.	0.1	0
128	Clinical Practice of Two Measurements of Home Blood Pressure on Each Occasion in Patients with Chronic Kidney Disease. CardioRenal Medicine, 2016, 6, 8-15.	1.9	0
129	Letter regarding â€œEstimated aortic blood pressure based on radial artery tonometry underestimates directly measured aortic blood pressure in patients with advancing chronic kidney disease staging and increasing arterial stiffnessâ€• Kidney International, 2017, 91, 757.	5.2	0
130	A case of microscopic polyangiitis initially presented with erythema multiformeâ€like skin eruptions. Journal of Cutaneous Immunology and Allergy, 2020, 3, 64-65.	0.3	0
131	We can have it all, but we just cannot have it all at once. Hypertension Research, 2020, 43, 835-836.	2.7	0
132	Clinical significance of selenium deficiency in hemodialysis patients. Nihon Toseki Igakkai Zasshi, 2021, 54, 191-201.	0.1	0
133	An increase in serum phosphate by sodium arginate.. Nihon Toseki Igakkai Zasshi, 2002, 35, 1583-1585.	0.1	0
134	7AM2-C-8 Development of Implantable Micro Hemodialysis System. The Proceedings of the Symposium on Micro-Nano Science and Technology, 2013, 2013.5, 253-254.	0.0	0
135	Helicobacter cinaedi infection in a polycystic kidney disease patient receiving hemodialysis. Nihon Toseki Igakkai Zasshi, 2014, 47, 501-506.	0.1	0
136	3P2-H07 Development of Implantable Micro Hemodialysis System(Nano/Micro Fluid System). The Proceedings of JSME Annual Conference on Robotics and Mechatronics (Robomec), 2014, 2014, _3P2-H07_1-_3P2-H07_2.	0.0	0
137	The Effects of Chronic, and Selective Vasopressin Receptor Blockade in Spontaneously Hypertensive Rats. International Heart Journal, 1995, 36, 538-538.	0.6	0
138	Acceptance of patients receiving peritoneal dialysis in geriatric health services facilities. Nihon Toseki Igakkai Zasshi, 2015, 48, 525-528.	0.1	0
139	30am2-PN-42 Biofouling of micro channel in implantable artificial kidney. The Proceedings of the Symposium on Micro-Nano Science and Technology, 2015, 2015.7, _30am2-PN--_30am2-PN-.	0.0	0
140	1P1-L06 Evaluation of Implantable Micro Hemodialysis System. The Proceedings of JSME Annual Conference on Robotics and Mechatronics (Robomec), 2015, 2015, _1P1-L06_1-_1P1-L06_2.	0.0	0
141	Fabrication and in vitro HF experiment for PES membrane coating f-DLC. The Proceedings of the Symposium on Micro-Nano Science and Technology, 2017, 2017.8, PN-29.	0.0	0
142	<i>In vivo</i> evaluation of biofouling on titanium microfluidic channel for implantable artificial kidney. The Proceedings of JSME Annual Conference on Robotics and Mechatronics (Robomec), 2017, 2017, 1A1-J06.	0.0	0
143	Appropriate dietary salt intake in patients receiving hemodialysis. Nihon Toseki Igakkai Zasshi, 2017, 50, 483-486.	0.1	0
144	Refusal of blood transfusion by a hemodialysis patient with renal anemia for religious reasons. Nihon Toseki Igakkai Zasshi, 2018, 51, 409-413.	0.1	0